Parecoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C19H18N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TUW81Y3CE, chemically known as propanamide, n-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)- but generally known as parecoxib, which bears US NIH Compound Identifier 119828. European Medicines Agency schedules Parecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03650MIG. The term PARECOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules parecoxib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule parecoxib under HS 29350090 and SITC 51580. As of Q4 2014, PARECOXIB remains the US FDA Preferred Term for this commodity. Parecoxib bears US NLM identifiers UMLS ID C0915142 and NCI Concept Code C66318. SMILES: S(=O)(=O)(NC(=O)CC)C1CCC(C2C(NOC2C)C2CCCCC2)CC1.